Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Juliana Martiniuc | Researchclopedia

Back to researchers

Juliana Martiniuc

7

Works

134

Citations

3

h-index

3

i10-index

Research Topics

Chronic Myeloid Leukemia Treatments Eosinophilic Disorders and Syndromes Chronic Lymphocytic Leukemia Research

Affiliations

Centre Hospitalier de Saint-Brieuc2019–2022

Centre Léon Bérard2022–2022

Yves Rocher (France)2019–2019

Top Works

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Franck E. Nicolini,Stéphanie Dulucq,et al.

2019108 citations

Fungal Plant Pathogen Control

Quinazolinone synthesis and applications

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Stéphanie Dulucq,Franck E. Nicolini,et al.

202214 citations

Lymphomas with kidney involvement: the French multicenter retrospective LyKID study

Milena Kohn,Alexandre Karras,et al.

202012 citations

Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Franck E. Nicolini,Stéphanie Dulucq,et al.

20230 citations

Supplementary Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Franck E. Nicolini,Stéphanie Dulucq,et al.

20230 citations

Supplementary Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Franck E. Nicolini,Stéphanie Dulucq,et al.

20230 citations

Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Franck E. Nicolini,Stéphanie Dulucq,et al.

20230 citations